NASDAQ:IXHL Incannex Healthcare Q4 2025 Earnings Results & Report $2.91 +0.01 (+0.34%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$2.92 +0.01 (+0.52%) As of 09:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Incannex Healthcare met analyst earnings expectations in its Q4 2025 results, released September 29, 2025. The company reported EPS of -$8.70 versus the -$8.70 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateSeptember 29, 2025TimeBefore Market OpensConference Call9:30 AM ET Incannex Healthcare EPS ResultsActual EPS-$8.70Consensus EPS -$8.70Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate2 of last 5 quartersIncannex Healthcare Revenue ResultsActual RevenueN/AExpected Revenue$0.20 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsIncannex Healthcare's Q1 2027 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual Report(10-K) Incannex Healthcare Q4 2025 Earnings FAQ Did Incannex Healthcare beat earnings estimates for Q4 2025? Incannex Healthcare (NASDAQ:IXHL) reported earnings of -$8.70 per share for Q4 2025, matching the consensus estimate of -$8.70. The report was announced on Monday, September 29, 2025. When is Incannex Healthcare's next earnings date? Incannex Healthcare's next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for Incannex Healthcare on the company's earnings history page. Incannex Healthcare Earnings HeadlinesIncannex Healthcare (NASDAQ:IXHL) Rating Lowered to Strong Sell at Zacks ResearchOctober 8, 2026 | americanbankingnews.comIncannex Healthcare (NASDAQ:IXHL) Stock Rating Lowered by Wall Street ZenOctober 3, 2026 | americanbankingnews.comThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.October 14 at 1:00 AM | Behind the Markets (Ad)Incannex Healthcare Inc. Reports Earnings Results for the Full Year Ended June 30, 2026September 25, 2026 | marketscreener.comMIncannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital PositionSeptember 9, 2026 | globenewswire.comIncannex Healthcare Doses First Patient in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep ApneaAugust 25, 2026 | quiverquant.comQSee More Incannex Healthcare Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Incannex Healthcare? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Incannex Healthcare and other key companies, straight to your email. Email Address About Incannex HealthcareIncannex Healthcare (NASDAQ:IXHL) Limited is an Australia-based clinical-stage pharmaceutical company developing therapies for conditions with significant unmet medical needs. The company’s research programs focus on cannabinoid-based medicines and psychedelic-assisted psychotherapy, with development activities spanning sleep disorders, respiratory and inflammatory diseases, pain, and mental health. Its pipeline includes IHL-42X, an investigational combination of dronabinol and acetazolamide being developed for obstructive sleep apnea. Incannex has also developed cannabinoid-based programs such as IHL-675A for inflammatory and fibrotic conditions, including idiopathic pulmonary fibrosis, and IHL-216A for traumatic brain injury and concussion. The company’s psychedelic medicine programs are designed to evaluate psilocybin-assisted psychotherapy for selected mental health conditions. Incannex conducts clinical development and related research in Australia and the United States and has pursued regulatory pathways in both markets. The company is headquartered in Melbourne, Australia, and is led by Chief Executive Officer and Managing Director Joel Latham. Its shares trade on the Nasdaq Capital Market under the symbol IXHL and on the Australian Securities Exchange under the symbol IHL.View Incannex Healthcare ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
